The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine intoxication in mouse

Experimental Neurology

Volumn 156, Issue 1, 1999, Pages 50-61

  Kurkowska Jastrzebska, Iwona ^a   Wrońska, Aneta ^a   Kohutnicka, Malgorzata ^a   Czlonkowski, Andrzej ^a   Czlonkowska, Anna ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Dexamethasone; Microglia; Neurodegeneration; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DEXAMETHASONE; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; HELPER CELL; IMMUNOPATHOLOGY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MICROGLIA; MOUSE; NERVE CELL LESION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; T LYMPHOCYTE SUBPOPULATION;

EID: 0344528794     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6993     Document Type: Article

References (68)

1. Adams D. A. Jr, Kalivas P. W., Miller C. A. The acute histopathology of MPTP in the mouse CNS. Brain. Res. Bull. 23:1989;1-17.
2. Aisen P. S., Davis K. L. Inflammatory mechanism in Alzheimer's disease: Implications for therapy. Am. J. Psychiat. 151:1994;1105-1113.
3. Akiyama H., Itagaki S., McGeer P. L. Major histocompability complex antigen expression on rat microglia following epidural kainic acid lesions. J. Neurosci. Res. 20:1988;147-157.
4. Akiyama H., McGeer P. L. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res. 489:1989;247-253.
5. Alsharif N. F., Hassaoun E., Baghi M., Lawson T., Stohs S. J. The effects of anti-TNF-alpha antibody and dexamethasone on TCDD-induced oxidative stress in mice. Pharmacology. 48:1994;127-136.
6. Arya S. K., Staal F. Wong, Gallo R. C. Dexamethasone-mediated inhibition of human T cell growth factor and γ-interferon messenger RNA. J. Immunol. 133:1984;273-276.
7. Banati R. B., Gehrmann J., Schubert P., Kreutzberg G. W. Cytotoxicity of microglia. Glia. 7:1993;111-118.
8. Beutler B., Krochin N., Milsark I. W., Luedke C., Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 232:1986;977-980.
9. Bieganowska K., Czlonkowska A., Bidziński A., Mierzewska H., Korlak J. Immunological changes in the MPTP induced Parkinson's disease mouse model. J. Neuroimmunol. 42:1993;33-38.
10. Brosnan C. F., Raine C. S. Mechanism of immune injury in multiple sclerosis. Brain Pathol. 6:1996;243-257.
11. Cash E., Zhang Y., Rott O. Microglia present myelin antigens to T cells after phagocytosis of oligodendrocytes. Cell. Immunol. 147:1993;129-138.
12. Cash E., Rott O. Microglial cells qualify as the stimulators of unprimed CD4+ and CD8+ T lymphocytes in the central nervous system. Clin. Exp. Immunol. 98:1994;313-318.
13. Chao C. C., Hu S., Close K., Choi C. S., Molitor T. W., Novick W. J., Peterson P. K. Cytokine release from microglia: Differential inhibition by pentoxifylline and dexamethasone. J. Infect. Dis. 166:1992;847-853.
14. Cleeter M. W. J., Cooper J. M., Schapira A. H. V. Irreversible inhibition of mitochondrial complex by 1-metyl-4-phenylpyridinium: Evidence for free radical involvement. J. Neurochem. 58:1992;786-789.
15. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., Czlonkowski A. Microglial reaction in MPTP induced Parkinson's disease mice model. Neurodegeneration. 5:1996;137-143.
16. Dalakas M. C. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: Present and future prospects. Ann. Neurol. 37:1995;S2-S13.
17. Dzenko K. A., Weltzien R. B., Pachter J. S. Suppression of a β-induced monocyte neurotoxicity by antiinflammatory compounds. J. Neuroimmunol. 80:1997;6-12.
18. Eddleston M., Mucke L. Molecular profile of reactive astrocytes - Implications for their role in neurologic disease. Neuroscience. 54:1993;15-36.
19. Engelhardt B., Conley F. C., Kilshaw P. J., Burcher E. C. Lymphocytes infiltrating the CNS during inflammation display a distinctive phenotype and bind to VCAM-1 but not to MadCAM-1. Int. Immunol. 7:1995;481-491.
20. Fertsch-Ruggio D., Schoenberg D. R., Vogel S. N. Induction of macrophage Ia antigen expression by rINF-γ and downregulation by INF-α/β and dexamethasone are regulated transcriptionally. J. Immunol. 141:1988;1582-1589.
21. Finsen B. R., Jorgensen M. B., Diemer N. H., Zimmer J. Microglial MHC antigen expression after ischemic and kainic acid lesions of the adult hippocampus. Glia. 7:1993;41-49.
22. Francis J. W., Von Visger J., Markelonis G. J., Oh T. H. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine in mouse striatum. Neurotoxicol. Teratol. 17:1995;7-12.
23. Gehrmann J., Bonnekoh P., Miyazawa T., Hossmann K. A., Kreutzberg G. W. The microglial reaction in the rat hippocampus following global ischemia: Immunoelectron microscopy. Acta Neuropathol. Berl. 84:1992;588-595.
24. +. Biochem. Biophys. Res. Commun. 170:1990;1049-1055.
25. Ii M., Sunamoto M., Ohnishi K., Ichimori Y. β-Amyloid protein-dependent nitric oxide production from microglia cells and neurotoxicity. Brain Res. 720:1996;93-100.
26. Jensen M. B., Finsen B. R., Gonzales B., Zimmer J. Cellular occurrence of MHC and leukocytic antigens in response to anterograde axonal degeneration in the rat facial dentata. Eur. J. Neurosci. 2:1989;254-256.
27. June C. H., Bluestone J. A., Nadler L. M., Thompson C. B. The B7 and CD28 receptor families. Immunol. Today. 15:1994;321-331.
28. Kiefer R., Kreutzberg G. W. Effects of dexamethasone on microglial activation in vivo: selective downregulation of major histocompability complex class II expression in regenerating facial nucleus. J. Neuroimmunol. 34:1991;99-108.
29. Kitamura Y., Itano Y., Kubo T., Namura Y. Suppresive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57B1/6 mice. Neuroimmunology. 50:1994;221-224.
30. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., Czlonkowska A. The microglial and astrocytic involvement in Parkinson's disease mice model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology. 39:1998;167-180.
31. Kreutzberg G. W. Microglia: A sensor for pathological events in the CNS. Trends Neurosci. 8:1996;305-369.
32. Kuhn W., Muller T., Nastos I., Poehlau D. The neuroimmune hypothesis in Parkinson's disease. Rev. Neurosci. 8:1997;29-34.
33. Lawson L. J. Leukocyte migration into the central nervous system. Immune Responses in the Nervous System. 1995;BIOS Scientific Publishers, Oxford. p. 27-60.
34. Liu B. J., Zheng M. R., Zhang S. Z., Dai F. P. Effects of antipsoriatic drugs of biosynthesis of platelet activating factor by human keratinocytes. Chin. Med. J. 107:1994;26-31.
35. Loughlin A. J., Woodroofe M. N., Cuzner M. L. Modulation of interferon-gamma-induced major histocompability complex class II and Fc receptor expression on isolated microglia by transforming growth factor-beta 1, interleukin 4, noradrenaline and glucocorticoids. Immunology. 79:1993;125-130.
36. Mackay C. R. T-cell memory: The connection between function, phenotype and migration pathways. Immunol. Today. 12:1991;189-192.
37. Matsumoto Y., Fujiwara M. In situ detection of class I and II major histocompability complex antigens in the rat central nervous system during experimental allergic encephalomyelitis. J. Neuroimmunol. 12:1986;265-277.
38. Matsuura K., Kabuto H., Makino H., Ogawa N. Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain. Brain Res. 733:1996;101-104.
39. McGeer P. L., McGeer E. G. The inflammatory response of the brain: Implication for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
40. McGeer P. L., Kawamata T., Walker D. G., Akiyama H., Tooyama I., McGeer E. G. Microglia in degenerative neurological disease. Glia. 7:1993;84-92.
41. McGeer P. L., McGeer E. G., Rogers J., Sibley J. Antiinflammatory drugs in Alzheimer's disease. Lancet. 335:1991;1037-1039.
42. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
43. McLean I. W., Nakane P. K. Periodate-lysine-paraformaldehyde fixative: A new fixative for immunoelectron microscopy. J. Histochem. Cytol. 22:1974;1077-1083.
44. 2. J. Neural Transm. 9:1995;87-92.
45. Mogi M., Harada M., Kondo T., Narabayashi H., Riederer P., Nagatsu T. Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci. Lett. 193:1995;129-132.
46. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1β levels, interleukin 6, epidermal growth factor and transforming growth factor α are elevated in the brain from Parkinsonian patients. Neurosci. Lett. 180:1994;147-150.
47. Moneta M. E., Gehrmann J., Topper R., Banati R. B., Kreutzberg G. W. Cell adhesion molecule expression in the regenerating rat facial nucleus. J. Neuroimmunol. 45:1993;203-206.
48. Morioka T. M., Kalehua A. N., Streit W. J. Progressive expression of immunomolecules on microglial cells in rat dorsal hippocampus following transient forebrain ischemia. Acta Neuropathol. 83:1992;149-157.
49. Nichols N. R., Osterburg H. H., Masters J. N., Millar S. L., Finch C. E. Messenger RNA for glial fibrillary acidic protein is decreased in rat brain following acute and chronic corticosterone treatment. Mol. Brain Res. 7:1990;1-7.
50. O'Callaghan J. P., Miller D. R., Reinhard J. F. Characterisation of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 521:1990;73-80.
51. O'Callaghan J. P., Brinton R. E., Mcewen B. S. Glucocorticoids regulate the concentration of glial fibrillary acidic protein throughout the brain. Brain Res. 494:1989;159-161.
52. Perry V. H., Gordon S. Macrophages and the central nervous system. Int. Rev. Cytol. 125:1991;203-244.
53. Ricaurte G. A., Irwin I., Forno L. S., Delanney L. E., Langston E., Langston J. W. Ageing and 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine induced degeneration of dopaminergic neurones in the substantia nigra. Brain Res. 403:1987;43-51.
54. Rogers J. Inflammation as a pathogenic mechanism on Alzheimer's disease. Arzneim.-Forsch. Drug. Res. 45:1995;439-442.
55. Rogers J., Kirby L. C., Hempleman S. R., Berry D. L., Mcgeer P. L., Kasniak A. W., Zalinski J., Cofield M., Manuskhani L., Wilson P., Kogan F. Clinical trial of indomethacin in Alzheimer disease. Neurology. 43:1993;1609-1611.
56. Shrikant P., Benveniste E. N. The central nervous system as an immunocompetent organ: Role of glial cells in antigen presentation. J. Immunol. 157:1996;1819-1822.
57. Steffen B. J., Butcher E. C., Engelhard B. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am. J. Pathol. 145:1994;189-201.
58. Steiner J. P., Hamilton G. S., Ross D. T. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl. Acad. Sci. USA. 94:1997;2019-2024.
59. Streit W. J., Graeber M. B., Kreutzberg G. W. Peripheral nerve lesion produces increased levels of major histocompatibility complex antigens in the central nervous system. J. Neuroimmunol. 21:1989;117-123.
60. Streit W. J., Graeber M. B., Kreutzberg G. W. Expression of Ia antigen on perivascular and microglial cells after sublethal and lethal motor neurone injury. Exp. Neurol. 105:1989;115-126.
61. Stromberg I., Bjorklund H., Dahl D., Jonnson G., Sunstrom E., Olson L. Astrocytic responses to dopaminergic denervations by 6-hydroxyl-dopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res. Bull. 17:1986;225-236.
62. Sundstrom E., Henriksson B. G., Mohammed A. H., Souverbie F. MPTP-treated mice: A useful model for Parkinson's disease. Toxin Induced Models of Neurological Disorders. 1994;Plenum, New York. p. 121-137.
63. Tanaka J., Fujita H., Matsuda S., Toku K., Sakanaka M., Maeda N. Glucocorticoid and mineralocorticoid receptors in microglial cells: The two receptors mediate differential effects of corticosteroids. Glia. 20:1997;23-37.
64. 123+. Cell. Mol. Neurobiol. 14:1994;99-104.
65. Von Knebel M., Doeberitz M., Koch S., Drzonek H., Zur Hausen H. Glucocorticoid hormones reduce the expression of major histocompability class I antigens on human epithelial cells. Eur. J. Immunol. 20:1990;35-40.
66. Walker W. S., Gatewood J., Olivas E., Askew D., Havenith C. E. Mouse microglial cells lines differing in constitutive and interferon-gamma-inducible antigen-presenting activities for naive and memory CD4+ and CD8+ T cells. J. Neuroimmunol. 63:1995;163-174.
67. Weller R. O., Engelhardt B., Phillips M. J. Lymphocyte targeting of the central nervous system: A review of afferent and efferent CNS-immune pathways. Brain Pathol. 6:1996;275-288.
68. Williams K., Ulvestad E., Antel J. P. B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur. J. Immunol. 24:1994;3031-3037.